Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680918 | 1.00 | IDO1 (0.35) | IDO1LMNATP53HTTRAB9A | |
| SCHEMBL23680931 | 0.91 | NR3C2 (0.34) | MAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29501811 | 0.91 | NR3C2 (0.34) | MAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29501787 | 0.88 | LMNA (0.34) | LMNATP53HTTRAB9A | |
| SCHEMBL23680937 | 0.88 | LMNA (0.34) | LMNATP53HTTRAB9A | |
| SCHEMBL23680928 | 0.81 | TP53 (0.34) | IDO1LMNATP53HTTRAB9A | |
| SCHEMBL29501780 | 0.81 | TP53 (0.34) | IDO1LMNATP53HTTRAB9A | |
| SCHEMBL23680925 | 0.81 | HTT (0.35) | LMNATP53HTTMAPTSLC6A2 | |
| SCHEMBL29047772 | 0.81 | HTT (0.35) | LMNATP53HTTMAPTSLC6A2 | |
| SCHEMBL29501742 | 0.81 | HTT (0.35) | LMNATP53HTTMAPTSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710429-B1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| US-11291205-B2 | Microbiocidal picolinamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291205-B2 | Microbiocidal picolinamide derivatives | CASP2, CASP1, MSR1 | IDO1 33/4885LMNA 3958/4885TP53 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.